Isla, D., Massuti, B., Lázaro, M., de Alda, L. R., Gordo, R., Ortega-Joaquín, N., & Oyagüez, I. (2020). Cost analysis of the management of brain metastases in patients with advanced ALK+ NSCLC: Alectinib versus crizotinib. Lung Cancer Manag.

Isla, Dolores, Bartomeu Massuti, Martín Lázaro, Lucía Ruiz de Alda, Rocio Gordo, Nuria Ortega-Joaquín, و Itziar Oyagüez. "Cost Analysis of the Management of Brain Metastases in Patients With Advanced ALK+ NSCLC: Alectinib Versus Crizotinib." Lung Cancer Manag 2020.

Isla, Dolores, et al. "Cost Analysis of the Management of Brain Metastases in Patients With Advanced ALK+ NSCLC: Alectinib Versus Crizotinib." Lung Cancer Manag 2020.